IDEAS home Printed from
MyIDEAS: Log in (now much improved!) to save this article

Sales Growth of New Pharmaceuticals Across the Globe: The Role of Regulatory Regimes

  • Stefan Stremersch


    (Erasmus School of Economics, Erasmus University Rotterdam, 3000 DR Rotterdam, The Netherlands, and IESE Business School, Universidad de Navarra, 08034 Barcelona, Spain)

  • Aurélie Lemmens


    (Erasmus School of Economics, Erasmus University Rotterdam, 3000 DR Rotterdam, The Netherlands)

Registered author(s):

    Prior marketing literature has overlooked the role of regulatory regimes in explaining international sales growth of new products. This paper addresses this gap in the context of new pharmaceuticals (15 new molecules in 34 countries) and sheds light on the effects of regulatory regimes on new drug sales across the globe. Based on a time-varying coefficient model, we find that differences in regulation substantially contribute to cross-country variation in sales. One of the regulatory constraints investigated, i.e., manufacturer price controls, has a positive effect on drug sales. The other forms of regulation such as restrictions of physician prescription budgets and the prohibition of direct-to-consumer advertising (DTCA) tend to hurt sales. The effect of manufacturer price controls is similar for newly launched and mature drugs. By contrast, regulations on physician prescription budgets and DTCA have a differential effect for newly launched and mature drugs. Whereas the former hurts mature drugs more, the latter has a larger effect on newly launched drugs. In addition to these regulatory effects, we find that national culture, economic wealth, and lagged sales also affect drug sales. Our findings may be used as input by managers for international launch and marketing decisions. They may also be used by public policy administrators to assess the role of regulatory regimes in pharmaceutical sales growth.

    If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.

    File URL:
    Download Restriction: no

    Article provided by INFORMS in its journal Marketing Science.

    Volume (Year): 28 (2009)
    Issue (Month): 4 (07-08)
    Pages: 690-708

    in new window

    Handle: RePEc:inm:ormksc:v:28:y:2009:i:4:p:690-708
    Contact details of provider: Postal:
    7240 Parkway Drive, Suite 300, Hanover, MD 21076 USA

    Phone: +1-443-757-3500
    Fax: 443-757-3515
    Web page:

    More information through EDIRC

    References listed on IDEAS
    Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:

    as in new window
    1. Margaret K. Kyle, 2007. "Pharmaceutical Price Controls and Entry Strategies," The Review of Economics and Statistics, MIT Press, vol. 89(1), pages 88-99, February.
    2. Ramkumar Janakiraman & Shantanu Dutta & Catarina Sismeiro & Philip Stern, 2008. "Physicians' Persistence and Its Implications for Their Response to Promotion of Prescription Drugs," Management Science, INFORMS, vol. 54(6), pages 1080-1093, June.
    3. Pradeep K. Chintagunta & Ramarao Desiraju, 2005. "Strategic Pricing and Detailing Behavior in International Markets," Marketing Science, INFORMS, vol. 24(1), pages 67-80, June.
    4. Charlotte H. Mason, 1990. "New Product Entries and Product Class Demand," Marketing Science, INFORMS, vol. 9(1), pages 58-73.
    5. Lynn, Michael & Zinkhan, George M & Harris, Judy, 1993. " Consumer Tipping: A Cross-Country Study," Journal of Consumer Research, Oxford University Press, vol. 20(3), pages 478-88, December.
    6. Jean O. Lanjouw, 2005. "Patents, Price Controls and Access to New Drugs: How Policy Affects Global Market Entry," Working Papers 61, Center for Global Development.
    7. Ngo, Long & Wand, Matthew P., 2004. "Smoothing with Mixed Model Software," Journal of Statistical Software, Foundation for Open Access Statistics, vol. 9(i01).
    8. van den Bulte, C. & Stremersch, S., 2003. "Contagion and heterogeneity in new product diffusion: An emperical test," ERIM Report Series Research in Management ERS-2003-077-MKT, Erasmus Research Institute of Management (ERIM), ERIM is the joint research institute of the Rotterdam School of Management, Erasmus University and the Erasmus School of Economics (ESE) at Erasmus University Rotterdam.
    9. Venkataraman, S. & Stremersch, S., 2007. "The Debate on Influencing Doctors’ Decisions: Are Drug Characteristics the Missing Link?," ERIM Report Series Research in Management ERS-2007-056-MKT, Erasmus Research Institute of Management (ERIM), ERIM is the joint research institute of the Rotterdam School of Management, Erasmus University and the Erasmus School of Economics (ESE) at Erasmus University Rotterdam.
    10. Tatyana Krivobokova & Göran Kauermann & Theofanis Archontakis, 2006. "Estimating the term structure of interest rates using penalized splines," Statistical Papers, Springer, vol. 47(3), pages 443-459, June.
    11. David M. Cutler & Alan M. Garber, 2003. "Frontiers in Health Policy Research, Volume 6," NBER Books, National Bureau of Economic Research, Inc, number cutl03-1, September.
    12. Gerard J. Tellis & Stefan Stremersch & Eden Yin, 2003. "The International Takeoff of New Products: The Role of Economics, Culture, and Country Innovativeness," Marketing Science, INFORMS, vol. 22(2), pages 188-208, October.
    13. Ciprian Crainiceanu & David Ruppert & Gerda Claeskens & M. P. Wand, 2005. "Exact likelihood ratio tests for penalised splines," Biometrika, Biometrika Trust, vol. 92(1), pages 91-103, March.
    14. Cutler David M. & Garber Alan M., 2003. "Introduction to Frontiers in Health Policy Research, Volume 6," Forum for Health Economics & Policy, De Gruyter, vol. 6(1), pages 1-6, January.
    15. Danzon, Patricia M. & Chao, Li-Wei, 2000. "Cross-national price differences for pharmaceuticals: how large, and why?," Journal of Health Economics, Elsevier, vol. 19(2), pages 159-195, March.
    16. Minhi Hahn & Sehoon Park & Lakshman Krishnamurthi & Andris A. Zoltners, 1994. "Analysis of New Product Diffusion Using a Four-Segment Trial-Repeat Model," Marketing Science, INFORMS, vol. 13(3), pages 224-247.
    17. Jianhua Z. Huang, 2002. "Varying-coefficient models and basis function approximations for the analysis of repeated measurements," Biometrika, Biometrika Trust, vol. 89(1), pages 111-128, March.
    18. Kauermann, Goran & Khomski, Pavel, 2006. "Additive two-way hazards model with varying coefficients," Computational Statistics & Data Analysis, Elsevier, vol. 51(3), pages 1944-1956, December.
    19. Kauermann, Goran, 2005. "Penalized spline smoothing in multivariable survival models with varying coefficients," Computational Statistics & Data Analysis, Elsevier, vol. 49(1), pages 169-186, April.
    20. Hubert Gatignon & Jehoshua Eliashberg & Thomas S. Robertson, 1989. "Modeling Multinational Diffusion Patterns: An Efficient Methodology," Marketing Science, INFORMS, vol. 8(3), pages 231-247.
    21. V. Kumar & Trichy V. Krishnan, 2002. "Multinational Diffusion Models: An Alternative Framework," Marketing Science, INFORMS, vol. 21(3), pages 318-330, July.
    22. Schwartz, Rebecca K. & Soumerai, Stephen B. & Avorn, Jerry, 1989. "Physician motivations for nonscientific drug prescribing," Social Science & Medicine, Elsevier, vol. 28(6), pages 577-582, January.
    23. Reuveni, Haim & Sheizaf, Boaz & Elhayany, Asher & Sherf, Michael & Limoni, Yehuda & Scharff, S. & Peled, Ronit, 2002. "The effect of drug co-payment policy on the purchase of prescription drugs for children with infections in the community," Health Policy, Elsevier, vol. 62(1), pages 1-13, October.
    24. Prasad A. Naik & Murali K. Mantrala & Alan G. Sawyer, 1998. "Planning Media Schedules in the Presence of Dynamic Advertising Quality," Marketing Science, INFORMS, vol. 17(3), pages 214-235.
    25. David M. Cutler & Alan M. Garber, 2003. "Introduction to "Frontiers in Health Policy Research, Volume 6"," NBER Chapters, in: Frontiers in Health Policy Research, Volume 6, pages -5 National Bureau of Economic Research, Inc.
    26. Roger M. Heeler & Thomas P. Hustad, 1980. "Problems in Predicting New Product Growth for Consumer Durables," Management Science, INFORMS, vol. 26(10), pages 1007-1020, October.
    27. Brent A. Coull & David Ruppert & M. P. Wand, 2001. "Simple Incorporation of Interactions into Additive Models," Biometrics, The International Biometric Society, vol. 57(2), pages 539-545, 06.
    28. Ramya Neelamegham & Pradeep K. Chintagunta, 2004. "Modeling and Forecasting the Sales of Technology Products," Quantitative Marketing and Economics (QME), Springer, vol. 2(3), pages 195-232, 09.
    29. Steven M. Shugan, 2003. "Editorial: Defining Interesting Research Problems," Marketing Science, INFORMS, vol. 22(1), pages 1-15.
    30. Mats Ekelund & Björn Persson, 2003. "Pharmaceutical Pricing in a Regulated Market," The Review of Economics and Statistics, MIT Press, vol. 85(2), pages 298-306, May.
    31. Murphy, Kevin M & Topel, Robert H, 2002. "Estimation and Inference in Two-Step Econometric Models," Journal of Business & Economic Statistics, American Statistical Association, vol. 20(1), pages 88-97, January.
    32. Puneet Manchanda & Pradeep K. Chintagunta, 2004. "Responsiveness of Physician Prescription Behavior to Salesforce Effort: An Individual Level Analysis," Marketing Letters, Springer, vol. 15(2_3), pages 129-145, 07.
    33. Sriram Venkataraman & Stefan Stremersch, 2007. "The Debate on Influencing Doctors' Decisions: Are Drug Characteristics the Missing Link?," Management Science, INFORMS, vol. 53(11), pages 1688-1701, November.
    34. Christophe Van den Bulte & Stefan Stremersch, 2004. "Social Contagion and Income Heterogeneity in New Product Diffusion: A Meta-Analytic Test," Marketing Science, INFORMS, vol. 23(4), pages 530-544, July.
    35. Wright, Donald J., 2004. "The drug bargaining game: pharmaceutical regulation in Australia," Journal of Health Economics, Elsevier, vol. 23(4), pages 785-813, July.
    36. Frank M. Bass & Trichy V. Krishnan & Dipak C. Jain, 1994. "Why the Bass Model Fits without Decision Variables," Marketing Science, INFORMS, vol. 13(3), pages 203-223.
    37. Min Ding & Jehoshua Eliashberg, 2008. "A Dynamic Competitive Forecasting Model Incorporating Dyadic Decision Making," Management Science, INFORMS, vol. 54(4), pages 820-834, April.
    38. Wedel, Michel & Leeflang, Peter S. H., 1998. "A model for the effects of psychological pricing in Gabor-Granger price studies," Journal of Economic Psychology, Elsevier, vol. 19(2), pages 237-260, April.
    39. Desiraju, Ramarao & Nair, Harikesh S. & Chintagunta, Pradeep, 2004. "Diffusion of New Pharmaceutical Drugs in Developing and Developed Nations," Research Papers 1950, Stanford University, Graduate School of Business.
    40. Dan Horsky & Leonard S. Simon, 1983. "Advertising and the Diffusion of New Products," Marketing Science, INFORMS, vol. 2(1), pages 1-17.
    41. Mehta, Abhilasha & Purvis, Scott C., 2003. "Consumer Response to Print Prescription Drug Advertising," Journal of Advertising Research, Cambridge University Press, vol. 43(02), pages 194-206, June.
    Full references (including those not matched with items on IDEAS)

    This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.

    When requesting a correction, please mention this item's handle: RePEc:inm:ormksc:v:28:y:2009:i:4:p:690-708. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Mirko Janc)

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If references are entirely missing, you can add them using this form.

    If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    This information is provided to you by IDEAS at the Research Division of the Federal Reserve Bank of St. Louis using RePEc data.